GlassScriptPhysician profile
Abid Yaqub
NPI 1275598666
$3,493.21
in general payments reported to CMS, 2019-2025
24 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $215 · 2021: $364 · 2022: $99.85 · 2023: $236 · 2024: $330 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $711.85 | 2019-2025 | Tepezza |
| Novo Nordisk INC | $314.86 | 2019-2024 | |
| Medtronic, INC. | $256.11 | 2023-2025 | Minimed 780g |
| Kyowa Kirin, INC. | $194.37 | 2024-2025 | Crysvita |
| Neurocrine Biosciences, INC. | $174.80 | 2025 | |
| Horizon Therapeutics Plc | $167.79 | 2019-2021 | |
| Sequel Med Tech, LLC | $149.33 | 2025 | Twiist |
| Medtronic Minimed, INC. | $138.79 | 2019 | |
| Amarin Pharma, INC. | $122.79 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $122.07 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.09 | 2021 | |
| Insulet Corporation | $113.33 | 2023 | Omnipod |
| Corcept Therapeutics | $111.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $110.76 | 2024 | |
| Mannkind Corporation | $92.95 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.66 | 2019 | |
| Ascendis Pharma Endocrinology INC | $91.82 | 2025 | Yorvipath |
| Lilly USA, LLC | $87.52 | 2022 | |
| Antares Pharma, INC. | $85.47 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $78.07 | 2019 | |
| Reflow Medical INC | $75.00 | 2025 | |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Yaqub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.